Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $43.17

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $43.17.

Several brokerages recently issued reports on ORKA. Leerink Partnrs upgraded shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Stifel Nicolaus started coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. TD Cowen started coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating for the company. Finally, Wedbush began coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective on the stock.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $28.81 on Friday. Oruka Therapeutics has a 12-month low of $18.72 and a 12-month high of $53.88. The company has a market capitalization of $34.86 million, a P/E ratio of -4.80 and a beta of 0.89.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, August 1st. The company reported ($25.92) earnings per share for the quarter. As a group, equities analysts predict that Oruka Therapeutics will post -1.62 EPS for the current year.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.